IPSEN (OTCMKTS:IPSEY) Shares Climb 7.1% – What’s Next?

by · The Markets Daily

Shares of IPSEN (OTCMKTS:IPSEY – Get Free Report) rose 7.1% during trading on Friday. The stock traded as high as $43.85 and last traded at $43.85. Approximately 1,175 shares traded hands during mid-day trading, a decline of 41% from the average daily volume of 1,991 shares. The stock had previously closed at $40.93.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Barclays upgraded IPSEN from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 17th. Finally, Jefferies Financial Group lowered IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Read Our Latest Analysis on IPSEY

IPSEN Stock Performance

The stock’s 50 day moving average is $44.38 and its two-hundred day moving average is $46.03.

IPSEN Company Profile

(Get Free Report)

Ipsen SA is a France-based biopharmaceutical company focused on developing and commercializing medicines for serious diseases. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with operations spanning research, clinical development, manufacturing and commercial activities.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and rare endocrine conditions, Dysport (abobotulinumtoxinA) for therapeutic and aesthetic uses, and Onivyde (a liposomal formulation of irinotecan) for pancreatic cancer.

Featured Articles